DJIA 16,880.36 0.00 0.00%
NASDAQ 4,462.90 0.00 0.00%
S&P 500 1,970.07 0.00 0.00%
market minute promo

AVANIR PHARMACEUTICALS (NASDAQ: AVNR)



company name or ticker

Thursday's ETF Movers: ILF, XPH

Top Biotech Stocks Under $5 With Huge Potential Upside

Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape

Avanir Pharmaceuticals Inc.: What Investors Must Watch in 2014

A big mid-stage disappointment sent Avanir's (AVNR) shares tumbling, but the future may not be as bad as some fear.

Will Mallinckrodt's Xartemis Change How We Treat Pain?

Mallinckrodt's (MNK) pain killer drug Xartemis may give doctors a drug that's less likely to be abused than current options.

IPO Preview: Concert Pharmaceuticals

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog

Avanir Pharmaceuticals' CEO Discusses F1Q 2014 Results - Earnings Call Transcript

Avanir Pharmaceuticals' Revenue Soars 62% on Strong Nuedexta Sales

Avanir's loss shrinks as higher sales of PBA drug Nuedexta counter a rise in R&D and marketing costs.

Avanir Files NDA for AVP-825 - Analyst Blog

See More Articles...